MedWatch

Analyst will focus on royalties defeat and increased costs in Genmab's Q1 report

When Genmab releases its first quarterly report later today, Sydbank analyst Søren Løntoft Hansen will search for news about the arbitration case the firm lost against Janssen and will keep an eye on expenses.

Photo: Joost Melis / Genmab / PR

Genmab’s cost developments and a lost arbitration case with its partner, Janssen, the pharmaceutical arm of Johnson & Johnson, will be the focus of the Danish biotech firm’s first quarterly report for 2022, which is slated to release later today, Wednesday, after trading closes in Denmark.

The market should already have gained a good understanding of how Genmab has performed on the top line, as a number of the firm’s collaboration partners have already publicized sales figures for drugs from which Genmab receives royalty payments.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs